跳转至内容
Merck
CN
  • DDX49 is an RNA helicase that affects translation by regulating mRNA export and the levels of pre-ribosomal RNA.

DDX49 is an RNA helicase that affects translation by regulating mRNA export and the levels of pre-ribosomal RNA.

Nucleic acids research (2018-04-05)
Sharad Awasthi, Mamta Verma, Arun Mahesh, Mohd Imran K Khan, Gayathri Govindaraju, Arumugam Rajavelu, Pavithra L Chavali, Sreenivas Chavali, Arunkumar Dhayalan
摘要

Among the proteins predicted to be a part of the DExD box RNA helicase family, the functions of DDX49 are unknown. Here, we characterize the enzymatic activities and functions of DDX49 by comparing its properties with the well-studied RNA helicase, DDX39B. We find that DDX49 exhibits a robust ATPase and RNA helicase activity, significantly higher than that of DDX39B. DDX49 is required for the efficient export of poly (A)+ RNA from nucleus in a splicing-independent manner. Furthermore, DDX49 is a resident protein of nucleolus and regulates the steady state levels of pre-ribosomal RNA by regulating its transcription and stability. These dual functions of regulating mRNA export and pre-ribosomal RNA levels enable DDX49 to modulate global translation. Phenotypically, DDX49 promotes proliferation and colony forming potential of cells. Strikingly, DDX49 is significantly elevated in diverse cancer types suggesting that the increased abundance of DDX49 has a role in oncogenic transformation of cells. Taken together, this study shows the physiological role of DDX49 in regulating distinct steps of mRNA and pre-ribosomal RNA metabolism and hence translation and potential pathological role of its dysregulation, especially in cancers.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
抗嘌呤霉素抗体,克隆 12D10, clone 12D10, from mouse
Sigma-Aldrich
单克隆抗 β-肌动蛋白抗体 小鼠抗, clone AC-74, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
抗-BrdU 抗体,小鼠单克隆抗体, clone BU-33, purified from hybridoma cell culture
Sigma-Aldrich
抗小鼠IgG(全分子)–FITC 山羊抗, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
MISSION® esiRNA, targeting human DDX49